NCT07288294Recruiting
PRImary Care Strategies for Weight Management (PRISM) Study
Primary-Care Strategies to Enhance Weight Management (PRISM) After Discontinuation of Anti-Obesity Medications
Source: ClinicalTrials.gov · Last updated 9 Jul 2026
Brief summary (registry, in English)
The goal of this clinical trial pilot is to determine the feasibility of an intervention to enhance weight management in patients who have stopped taking anti-obesity/weight management medications in primary care. The main questions it aims to answer are: * Can patients be recruited into the study efficiently? * Is the program acceptable to patients? * Can the study be conducted efficiently? The new program will be compared to usual care.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 214 (estimated)
- First submitted
- 14 Nov 2025
- Start date
- 4 Jun 2026
- Primary completion date
- 1 Apr 2028
- Lead sponsor
- Rush University Medical Center
- Diseases
- Obesity
- NCT number
- NCT07288294
What you commit to
- Study type: Interventional
- Planned participants: 214
- From 4 Jun 2026 to the primary completion date, 1 Apr 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Bariatric surgery in the past 2 years or planned bariatric surgery.
- Concurrent engagement with other behavioral treatments for obesity (for randomized phase only).
- Medication obtained from online/compound pharmacies or prescription from specialty clinic without a prescription from primary care team at the time of enrollment
Other illness
- Diagnosis of diabetes (type 1 or type 2)
- Medical contraindications to treatment, including significant cognitive impairment, active substance abuse based on the World Health Organization's ASSIST screener, or serious medical illness (e.g., stage 3 or 4 heart failure, cancer, renal failure, etc.)
Other
- Not fluent in English
- Current or planned pregnancy
- Body mass index ≥60 kg/m2, due to increased injury risk with exercise
- Body weight ≥ 375 pounds (scale capacity with a margin for regain)
- No access to home WIFI or a smartphone with data available
- Another member of the household is enrolled in the study
Who the study is looking for
- For run-in: prescribed liraglutide, semaglutide, or tirzepatide or newer medication approved by the FDA for long-term use for obesity treatment for the purpose of weight managment by a primary care provider at Rush University System for Health and have received at least one dose of the medication concurrent with enrollment in the study.
- For randomization: discontinue their prescribed anti-obesity medication.
- Age 18+
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rush University Medical Center Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.